Affymax, Inc. is a biopharmaceutical company previously committed to developing novel drugs to improve the treatment of serious and often life-threatening conditions. Our vision was to become a leader in the nephrology and specialty care space by delivering innovative therapeutic offerings to patients and healthcare providers before a nationwide voluntary recall of OMONTYS® (peginesatide) Injection in February 2013. In March 2013 Affymax commenced a review of strategic alternatives.
|Type||Public / Private|
Top 5 Recent Tweets
|January 11, 2020||ElementaryValue||New blog post is up. Another NOL stub for all you fans of special situations. Affymax Inc. (AFFY) - A Couchman co… https://t.co/GomcgqFErC|
|January 17, 2020||WeekHerald||Affymax $AFFY Shares Pass Above 200 Day Moving Average of $0.02 https://t.co/3O2hohMhHS|
|January 16, 2020||dakotafinancial||Affymax $AFFY Share Price Passes Above 200-Day Moving Average of $0.02 https://t.co/nvTaYbCE8a|